CTLT
Catalent, Inc. [CTLT] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CTLT Stock Summary
Top CTLT Correlated Resources
CTLT
Top 10 Correlated ETFs
CTLT
Top 10 Correlated Stocks
CTLT
In the News
Activist Elliott makes inroads at Catalent to build value. Here's what could happen next
Elliott recently entered a cooperation agreement with Catalent. This could pave the way for some major changes at the pharmaceutical company.
Catalent gets NYSE notice that it's not in compliance with listing rules over late 10-K filing
Drug manufacturer Catalent Inc. CTLT, +1.74% said Friday it has received a notice from the New York Stock Exchange informing it that's it's not in compliance with listing rules due to a delay in filing its annual form 10-K with the Securities and Exchange Commission. The company has six months from Sept.
Why Catalent Stock Zoomed 12% Higher This Week
The company delivered a better-than-expected quarterly earnings report. It beat on revenue, and only narrowly missed on earnings.
Catalent (CTLT) Gains Post Deal With Elliott and Earnings Report
Catalent's (CTLT) deal with Elliott and earnings report boost its shares. The company will likely improve its value and growth with the agreement and its strategic investments.
Why Catalent Stock Surged Nearly 5% Higher Today
The contract drug manufacturer posted steep declines in key fundamentals in its fiscal fourth quarter. Still, it booked more revenue than analysts expected; guidance also topped expectations.
Catalent, Inc. (CTLT) Q4 2023 Earnings Call Transcript
Catalent, Inc. (NYSE:CTLT ) Q4 2023 Earnings Conference Call August 29, 2023 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations John Greisch - Executive Chair, Board Alessandro Maselli - President and CEO Matti Masanovich - Senior Vice President and CFO Conference Call Participants Tejas Savant - Morgan Stanley David Windley - Jefferies Jacob Johnson - Stephens Jack Meehan - Nephron Research Sean Dodge - RBC Capital Markets John Sourbeer - UBS Justin Bowers - Deutsche Bank Derik De Bruin - Bank of America Max Smock - William Blair Rachel Vatnsdal - J.P. Morgan Tim Daley - Wells Fargo Operator Good morning, ladies and gentlemen.
Catalent (CTLT) Preliminary Q4 Revenues Dampened by Lower Sales
Catalent (CTLT) records lower revenues in Biologics segment in its fourth-quarter fiscal 2023, resulting in overall soft preliminary performance.
Shares of Wegovy Partner Catalent Jump After Striking Deal With Activist Investor Elliott
Catalent (CTLT) shares surged more than 5% in early trading on Tuesday after the struggling drugmaker secured a deal with activist investor Elliott Investment Management.
Catalent nears deal with Elliott Investment Management; will explore company sale
Catalent Inc is close to a settlement deal with activist investor Elliott Investment Management, which will include the appointment new directors and a pledge to review strategic alternatives such as a sale of the company, Reuters reported, citing sources familiar with the matter. The media outlet noted the US-based contract drugmaker is set to add four new directors proposed by Elliott to its board, including Elliott's global head of engagement, Steven Barg, a former Goldman Sachs (NYSE:GS) banker, along with former Pfizer chief financial officer Frank D'Amelio.
Catalent (CTLT) Stock Gains on Elliott Deal
Catalent (NYSE: CTLT ) stock is getting a boost on Tuesday after the consumer health company reached an agreement with Elliott Investment Management. This has Catalent adding four new directors to its Board while also agreeing to conduct a strategic review.
CTLT Financial details
CTLT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-06-30
| Metric | History | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 17.46 | 20.63 | 23.8 | 27.43 | 23.62 | |
| Net income per share | 0.95 | 1.47 | 3.48 | 2.95 | -1.28 | |
| Operating cash flow per share | 1.72 | 2.94 | 2.58 | 2.49 | 1.44 | |
| Free cash flow per share | 0.21 | -0.17 | -1.51 | -1.26 | -1.78 | |
| Cash per share | 2.4 | 6.35 | 5.76 | 3.06 | 1.55 | |
| Book value per share | 11.66 | 19.33 | 23.3 | 27.24 | 25.61 | |
| Tangible book value per share | -10.19 | -3.07 | 3.45 | 4.14 | 25.61 | |
| Share holders equity per share | 11.66 | 19.33 | 23.3 | 27.24 | 25.61 | |
| Interest debt per share | 21.29 | 20.96 | 19.95 | 24.57 | 27.81 | |
| Market cap | 7.89B | 11B | 18.16B | 18.88B | 7.85B | |
| Enterprise value | 10.5B | 13.06B | 20.51B | 22.64B | 12.42B | |
| P/E ratio | 57.42 | 49.82 | 31.05 | 36.38 | -33.83 | |
| Price to sales ratio | 3.13 | 3.55 | 4.54 | 3.91 | 1.84 | |
| POCF ratio | 31.85 | 24.97 | 41.95 | 43.01 | 30.07 | |
| PFCF ratio | 266.53 | -431.18 | -71.8 | -85.44 | -24.37 | |
| P/B Ratio | 4.69 | 3.79 | 4.64 | 3.94 | 1.69 | |
| PTB ratio | 4.69 | 3.79 | 4.64 | 3.94 | 1.69 | |
| EV to sales | 4.17 | 4.22 | 5.13 | 4.69 | 2.9 | |
| Enterprise value over EBITDA | 36.17 | 32.85 | 31.9 | 31.14 | 157.18 | |
| EV to operating cash flow | 42.4 | 29.66 | 47.37 | 51.56 | 47.58 | |
| EV to free cash flow | 354.83 | -512.15 | -81.06 | -102.43 | -38.56 | |
| Earnings yield | 0.02 | 0.02 | 0.03 | 0.03 | -0.03 | |
| Free cash flow yield | 0 | 0 | -0.01 | -0.01 | -0.04 | |
| Debt to equity | 1.76 | 1.04 | 0.83 | 0.88 | 1.05 | |
| Debt to assets | 0.48 | 0.39 | 0.36 | 0.4 | 0.45 | |
| Net debt to EBITDA | 9 | 5.19 | 3.65 | 5.16 | 57.84 | |
| Current ratio | 2.08 | 2.57 | 2.44 | 2.72 | 1.78 | |
| Interest coverage | 0.56 | 1.14 | 3.22 | 2.84 | -0.74 | |
| Income quality | 1.8 | 2 | 0.74 | 0.85 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0.16 | 0.04 | 0.01 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.51 | 0.43 | 0.37 | 0.39 | 0 | |
| Capex to operating cash flow | -0.88 | -1.06 | -1.58 | -1.5 | -2.23 | |
| Capex to revenue | -0.09 | -0.15 | -0.17 | -0.14 | -0.14 | |
| Capex to depreciation | -0.95 | -1.84 | -2.37 | -1.75 | 0 | |
| Stock based compensation to revenue | 0.01 | 0.02 | 0.01 | 0.01 | 0 | |
| Graham number | 15.81 | 25.29 | 42.73 | 42.52 | 27.18 | |
| ROIC | 0.01 | 0.01 | 0.04 | 0.03 | -0.01 | |
| Return on tangible assets | 0.05 | 0.05 | 0.1 | 0.08 | -0.02 | |
| Graham Net | -24.21 | -20.89 | -18.99 | -22.92 | -26.26 | |
| Working capital | 725.1M | 1.4B | 1.72B | 1.84B | 1.17B | |
| Tangible asset value | -1.47B | -460.5M | 579M | 729M | 4.64B | |
| Net current asset value | -3.11B | -2.58B | -2.28B | -2.8B | -3.47B | |
| Invested capital | 1.76 | 1.04 | 0.83 | 0.88 | 1.05 | |
| Average receivables | 636.1M | 777.25M | 925.05M | 1.03B | 1.01B | |
| Average payables | 223.95M | 288.4M | 353M | 403M | 424M | |
| Average inventory | 233.15M | 290.5M | 443.4M | 632.5M | 733M | |
| Days sales outstanding | 103.85 | 98.86 | 92.39 | 79.46 | 83.4 | |
| Days payables outstanding | 54.51 | 55.5 | 53.11 | 48.2 | 48.46 | |
| Days of inventory on hand | 54.81 | 55.99 | 77.66 | 80.37 | 86.71 | |
| Receivables turnover | 3.51 | 3.69 | 3.95 | 4.59 | 4.38 | |
| Payables turnover | 6.7 | 6.58 | 6.87 | 7.57 | 7.53 | |
| Inventory turnover | 6.66 | 6.52 | 4.7 | 4.54 | 4.21 | |
| ROE | 0.08 | 0.08 | 0.15 | 0.11 | -0.05 | |
| Capex per share | -1.51 | -3.11 | -4.08 | -3.75 | -3.22 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q4
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 7.29 | 5.68 | 6.38 | 5.73 | 5.9 | |
| Net income per share | 1.04 | 0 | 0.45 | -1.25 | -0.48 | |
| Operating cash flow per share | 0.38 | -0.51 | 1.19 | -0.35 | 1.12 | |
| Free cash flow per share | -0.92 | -1.34 | 0.26 | -1.12 | 0.41 | |
| Cash per share | 2.99 | 1.92 | 2.61 | 1.39 | 1.55 | |
| Book value per share | 26.64 | 26.11 | 27.29 | 25.98 | 25.61 | |
| Tangible book value per share | 4.05 | 4.19 | 3.62 | 3.69 | 25.61 | |
| Share holders equity per share | 26.64 | 26.11 | 27.29 | 25.98 | 25.61 | |
| Interest debt per share | 23.52 | 23.61 | 27.29 | 27.07 | 27.09 | |
| Market cap | 19.31B | 13.02B | 8.1B | 11.89B | 7.85B | |
| Enterprise value | 23.07B | 16.96B | 12.52B | 16.49B | 12.42B | |
| P/E ratio | 25.68 | 0 | 25.01 | -13.1 | -22.81 | |
| Price to sales ratio | 14.71 | 12.74 | 7.05 | 11.47 | 7.35 | |
| POCF ratio | 279.89 | -141.57 | 37.86 | -185.84 | 38.66 | |
| PFCF ratio | -116.34 | -54.04 | 176.13 | -58.88 | 104.64 | |
| P/B Ratio | 4.03 | 2.77 | 1.65 | 2.53 | 1.69 | |
| PTB ratio | 4.03 | 2.77 | 1.65 | 2.53 | 1.69 | |
| EV to sales | 17.57 | 16.6 | 10.9 | 15.9 | 11.63 | |
| Enterprise value over EBITDA | 94.92 | 106.67 | 52.41 | -785.26 | -129.35 | |
| EV to operating cash flow | 334.28 | -184.36 | 58.53 | -257.66 | 61.17 | |
| EV to free cash flow | -138.95 | -70.38 | 272.28 | -81.64 | 165.56 | |
| Earnings yield | 0.01 | 0 | 0.01 | -0.02 | -0.01 | |
| Free cash flow yield | -0.01 | -0.02 | 0.01 | -0.02 | 0.01 | |
| Debt to equity | 0.88 | 0.9 | 0.99 | 1.03 | 1.05 | |
| Debt to assets | 0.4 | 0.41 | 0.44 | 0.45 | 0.45 | |
| Net debt to EBITDA | 15.44 | 24.75 | 18.51 | -218.9 | -47.59 | |
| Current ratio | 2.72 | 2.86 | 1.91 | 1.84 | 1.78 | |
| Interest coverage | 4.47 | 1.88 | 2.94 | -0.49 | -1.85 | |
| Income quality | 0.37 | 46 | 2.64 | 0.28 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.39 | 0.39 | 0.38 | 0.37 | 0 | |
| Capex to operating cash flow | -3.41 | 1.62 | -0.79 | 2.16 | -0.63 | |
| Capex to revenue | -0.18 | -0.15 | -0.15 | -0.13 | -0.12 | |
| Capex to depreciation | -2.35 | -1.51 | -1.63 | -1.3 | 0 | |
| Stock based compensation to revenue | 0.01 | 0.02 | 0.01 | 0.01 | 0 | |
| Graham number | 25.02 | 0 | 16.62 | 27.08 | 16.55 | |
| ROIC | 0.01 | 0 | 0.01 | 0 | -0.01 | |
| Return on tangible assets | 0.03 | 0 | 0.01 | -0.03 | -0.01 | |
| Graham Net | -22.42 | -20.57 | -23.65 | -26.06 | -26.26 | |
| Working capital | 1.84B | 1.76B | 1.39B | 1.25B | 1.17B | |
| Tangible asset value | 729M | 754M | 652M | 668M | 4.64B | |
| Net current asset value | -2.8B | -2.81B | -3.32B | -3.39B | -3.47B | |
| Invested capital | 0.88 | 0.9 | 0.99 | 1.03 | 1.05 | |
| Average receivables | 1.17B | 1.25B | 1.45B | 1.25B | 1.01B | |
| Average payables | 411M | 400M | 373M | 380.5M | 410.5M | |
| Average inventory | 699.5M | 727.5M | 797M | 792.5M | 754M | |
| Days sales outstanding | 72.04 | 126.9 | 113.58 | 91.04 | 82.33 | |
| Days payables outstanding | 45.93 | 44.65 | 43.35 | 41.38 | 46.13 | |
| Days of inventory on hand | 76.58 | 88.7 | 99.33 | 78.13 | 82.55 | |
| Receivables turnover | 1.25 | 0.71 | 0.79 | 0.99 | 1.09 | |
| Payables turnover | 1.96 | 2.02 | 2.08 | 2.18 | 1.95 | |
| Inventory turnover | 1.18 | 1.01 | 0.91 | 1.15 | 1.09 | |
| ROE | 0.04 | 0 | 0.02 | -0.05 | -0.02 | |
| Capex per share | -1.31 | -0.83 | -0.93 | -0.76 | -0.71 |
CTLT Frequently Asked Questions
What is Catalent, Inc. stock symbol ?
Catalent, Inc. is a US stock , located in Somerset of Nj and trading under the symbol CTLT
Is Catalent, Inc. buy or a sell ?
6 stock analysts have 6 predictions with a medium analyst target price of $84.67. The lowest prediction is $41 and the highest is $132
What is CTLT stock prediction ?
What is Catalent, Inc. stock quote today ?
Catalent, Inc. stock price is $45.2 today.
Is Catalent, Inc. stock public?
Yes, Catalent, Inc. is a publicly traded company.
Company Profile
- Volume Average 2.51M
- Market Capitalization 8.17B
- Employee 17.8K
- CEO Mr. Alessandro Maselli
- Headquarters Somerset,NJ,US
- IPO Date 2014-07-31
-
Website
https://www.catalent.com 
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
